share_log

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7

瑞士信貸維持Pear Therapeutics的跑贏大盤,將目標股價下調至7美元
Benzinga Real-time News ·  2022/11/15 09:02

Credit Suisse analyst Judah Frommer maintains Pear Therapeutics (NASDAQ:PEAR) with a Outperform and lowers the price target from $9 to $7.

瑞士信貸分析師Judah Frommer維持Pear Therapeutics(納斯達克股票代碼:PEAR)的跑贏大盤,並將目標股價從9美元下調至7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論